$13.81
-0.14-1%
Last update: Nov 12, 5:45 PM
Anika Therapeutics Inc
ANIKNASDAQ
Anika Therapeutics rose 38.1% from $10.10 to $13.95, ahead of the S&P 500's +10.8%. Its worst day was Nov 6 (−24.7%), and its low came Jan 28 at $9.13.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Anika Therapeutics closed at its lowest level of the year, 9.6% below where the year started.
−0.2% · S&P 500 0.0%
EPS of $0.31 beat the $-0.06 estimate on $30.6M revenue (est. $28.9M); FY revenue guidance of $114.0M–$122.5M against the $114.2M consensus.
Story events cover the past 12 months · Times ET
+16.9% · S&P 500 −0.6%
EPS of $0.27 beat the $-0.04 estimate on $29.6M revenue (est. $28.1M); FY revenue guidance of $114.0M–$122.5M against the $117.2M consensus.
−18.8% · S&P 500 0.0%
EPS of $0.42 beat the $-0.01 estimate on $32.6M revenue (est. $29.2M); FY revenue guidance of $118.5M–$124.1M against the $118.6M consensus.
+6.7% · S&P 500 −1.5%
Anika Therapeutics closed at its highest level of the year, 118.1% above where the year started.
+3.8% · S&P 500 +0.3%
EPS of $0.29 beat the $0.14 estimate on $30.6M revenue (est. $29.4M); FY revenue guidance of $119.6M–$124.1M against the $121.6M consensus.
−24.7%, the year's worst day · S&P 500 +0.3%
Where it ended: a close of $13.95 on Nov 11, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $0.12, revenue est. $29.7M).
Nothing in the past 12 months.
All ANIK dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ANIK and SPY from Benzinga historical bars. Not investment advice.
